Lilly’s retatrutide outshines Ozempic on weight loss, blood sugar control in trial

Eli Lilly said on Wednesday its experimental next-generation obesity drug, retatrutide, outperformed Novo Nordisk’s Ozempic on blood sugar control and delivered more than double…

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.bnnbloomberg.ca)